	US 12,465,611 B2
	Compositions and methods for treatment of depression and other disorders
Magid Abraham, Tiburon, CA (US); and Ken Gillman, Bucasia (AU)
Assigned to NEURAWELL THERAPEUTICS, Tiburon, CA (US)
Appl. No. 17/431,422
Filed by Neurawell Therapeutics, Tiburon, CA (US)
PCT Filed Feb. 18, 2020, PCT No. PCT/US2020/018567 § 371(c)(1), (2) Date Aug. 16, 2021, PCT Pub. No. WO2020/168337, PCT Pub. Date Aug. 20, 2020.
Claims priority of provisional application 62/806,831, filed on Feb. 17, 2019.
Prior Publication US 2022/0117975 A1, Apr. 21, 2022
Int. Cl. A61K 31/55 (2006.01); A61K 31/135 (2006.01); A61K 31/137 (2006.01); A61K 31/138 (2006.01); A61K 31/15 (2006.01); A61K 31/42 (2006.01); A61K 31/5375 (2006.01); A61P 25/24 (2006.01)

CPC A61K 31/55 (2013.01) [A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/138 (2013.01); A61K 31/15 (2013.01); A61K 31/42 (2013.01); A61K 31/5375 (2013.01); A61P 25/24 (2018.01)]

9 Claims

1. A pharmaceutical composition comprising:

(i) phenelzine or a pharmaceutically acceptable salt thereof,

(ii) a norepinephrine-reuptake-inhibitor (NRI) selected from protriptyline and desipramine, or a pharmaceutically acceptable salt thereof, and

(iii) a pharmaceutically acceptable carrier,

wherein the NRI is formulated as a controlled-release dosage form, wherein phenelzine or the pharmaceutically acceptable salt thereof is formulated as a controlled-release dosage form, and wherein the NRI and phenelzine or the pharmaceutically acceptable salt thereof are released over different time periods,

wherein the phenelzine or the pharmaceutically acceptable salt thereof is present in a therapeutically effective amount, and

wherein the composition does not contain droxidopa.